Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 15, 2011

FDA approves IntelGenx anti-depressant

The US Food and Drug Administration (FDA) has approved IntelGenxs' anti-depressant CPI-300 to treat patients with major depressive disorder.

The US Food and Drug Administration (FDA) has approved IntelGenxs’ anti-depressant CPI-300 to treat patients with major depressive disorder.

CPI-300 is a single dose 450mg formulation of bupropion hydrochloride.

IntelGenx president and CEO Horst Zerbe said that physicians would embrace CPI-300 as a safe alternative for patients requiring high-dose anti-depressant therapy.

”So we now turn our focus towards the commercialisation of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe added.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU